Literature DB >> 9237102

Immobilized anti-CD3 mAb induces anergy in murine naive and memory CD4+ T cells in vitro.

J G Chai1, R I Lechler.   

Abstract

The induction of non-responsiveness in resting murine CD4+ T cells was investigated using immobilized anti-CD3 mAb. Incubation of freshly isolated CD4+ T cells with immobilized anti-CD3 mAb led to apoptosis in 40-60% cells. The surviving cells were profoundly non-responsive to subsequent mitogenic stimulation. The non-responsive state was characterized by a lack of IL-2 production and hyper-responsiveness to added IL-2, but was not explained by further activation-induced cell death. The induction of non-responsiveness was not due to modulation of the TCR-CD3 complex, and required partial activation of the T cells in that it was accompanied by an increase in cell size and was inhibited by addition of cyclosporin A. Finally, analysis of anti-CD3-mediated responses in naive and memory CD4+ T cells, separated on the basis of CD44 expression, showed that both naive and memory T cells have similar sensitivity to immobilized anti-CD3 mAb-induced activation, apoptosis and anergy. These results demonstrate that TCR-CD3 engagement on freshly isolated resting CD4+ naive and memory T cells, In the absence of co-stimulation, as achieved by plastic-immobilized anti-CD3 mAb, induces both anergy and cell death.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9237102     DOI: 10.1093/intimm/9.7.935

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  11 in total

Review 1.  The contributions of T-cell anergy to peripheral T-cell tolerance.

Authors:  R Lechler; J G Chai; F Marelli-Berg; G Lombardi
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

2.  Oral administration of the lactic acid bacterium Pediococcus acidilactici attenuates atherosclerosis in mice by inducing tolerogenic dendritic cells.

Authors:  Taiji Mizoguchi; Kazuyuki Kasahara; Tomoya Yamashita; Naoto Sasaki; Keiko Yodoi; Takuya Matsumoto; Takuo Emoto; Tomohiro Hayashi; Naoki Kitano; Naofumi Yoshida; Hilman Zulkifli Amin; Ken-Ichi Hirata
Journal:  Heart Vessels       Date:  2017-02-08       Impact factor: 2.037

3.  Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation.

Authors:  Lan Wu; Edward Seung; Ling Xu; Ercole Rao; Dana M Lord; Ronnie R Wei; Virna Cortez-Retamozo; Beatriz Ospina; Valeriya Posternak; Gregory Ulinski; Peter Piepenhagen; Elisa Francesconi; Nizar El-Murr; Christian Beil; Patrick Kirby; Aiqun Li; Jennifer Fretland; Rita Vicente; Gejing Deng; Tarik Dabdoubi; Beatrice Cameron; Thomas Bertrand; Paul Ferrari; Stéphanie Pouzieux; Cendrine Lemoine; Catherine Prades; Anna Park; Huawei Qiu; Zhili Song; Bailin Zhang; Fangxian Sun; Marielle Chiron; Srinivas Rao; Katarina Radošević; Zhi-Yong Yang; Gary J Nabel
Journal:  Nat Cancer       Date:  2019-11-18

Review 4.  Role of the CTLA-4 receptor in T cell activation and immunity. Physiologic function of the CTLA-4 receptor.

Authors:  P Scheipers; H Reiser
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

5.  Non-mitogenic anti-CD3F(ab')2 monoclonal antibody: a novel approach to control herpetic stromal keratitis.

Authors:  Pranita P Sarangi; Bumseok Kim; Barry T Rouse
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-08-08       Impact factor: 4.799

Review 6.  Molecular regulation of T-cell anergy.

Authors:  Yan Zheng; Yuanyuan Zha; Thomas F Gajewski
Journal:  EMBO Rep       Date:  2008-01       Impact factor: 8.807

7.  Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells.

Authors:  Longchao Liu; Jiahui Chen; Joonbeom Bae; Huiyu Li; Zhichen Sun; Casey Moore; Eric Hsu; Chuanhui Han; Jian Qiao; Yang-Xin Fu
Journal:  Nat Biomed Eng       Date:  2021-11-01       Impact factor: 29.234

8.  Targeting transcriptional coregulator OCA-B/Pou2af1 blocks activated autoreactive T cells in the pancreas and type 1 diabetes.

Authors:  Heejoo Kim; Jelena Perovanovic; Arvind Shakya; Zuolian Shen; Cody N German; Andrea Ibarra; Jillian L Jafek; Nai-Pin Lin; Brian D Evavold; Danny H-C Chou; Peter E Jensen; Xiao He; Dean Tantin
Journal:  J Exp Med       Date:  2021-03-01       Impact factor: 14.307

9.  Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo.

Authors:  Yan Zheng; Yuanyuan Zha; Gregory Driessens; Frederick Locke; Thomas F Gajewski
Journal:  J Exp Med       Date:  2012-11-05       Impact factor: 14.307

10.  Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells.

Authors:  Katarzyna Urbanska; Rachel C Lynn; Caitlin Stashwick; Archana Thakur; Lawrence G Lum; Daniel J Powell
Journal:  J Transl Med       Date:  2014-12-13       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.